Board of Directors

Dr. Lance Willsey was appointed Chairman of the Board on September 30, 2024. He was appointed member of the Board of Directors in December 2023. Dr. Lance Willsey, M.S., M.D. is a urologist who has an aggregate of 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab Harvard University and the Dana Farber Cancer Institute. Lance is a founding Partner of Healthcare fund DCF Capital. He also actively participated in boards as a Director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023. Lance helped guide the two companies through their IPO process as well as subsequent financings. He also has extensive experience in corporate governance having served on audit, compensation, finance and scientific advisory committees.

Marie Meynadier was appointed as a member of the Board of Directors in June 2020. Marie Meynadier currently serves on the Boards of Directors of several medical technology companies in Europe and North America. From 1999 through 2019, she served at EOS Imaging as its CEO. Prior to EOS Imaging, Ms. Meynadier served as CEO at Biospace Lab, a preclinical imaging company she developed and turned to profitability. Ms. Meynadier received a degree in electrical engineering from Sup Télécom, Paris, and her Ph.D. in physics from Ecole Normale Supérieure Ulm, Paris.

Ryan Rhodes was appointed as a member of the Board of Directors in August 2023. Ryan was appointed Chief Executive Officer of Company on May 1, 2023, to lead, strengthen and accelerate the Company’s corporate strategy and development. Mr. Rhodes is a passionate executive with over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Ryan served as the CEO of Restoration Robotics, the global leader in robotic aesthetic medicine where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Ryan spent over 13 years at Intuitive Surgical, the global leader in medical robotics where he was a key architect of the company’s multi-procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Ryan holds a B.A in Public Administration from San Diego State University.

Ms. Schulz was appointed as a member of the Board of Directors in June 2024. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies throughout the life sciences industry. She has deep experience guiding companies to execute a broad range of corporate deals including collaboration agreements, corporate spin-offs, reorganizations, and mergers and acquisitions, with personal involvement in over 100 total equity and debt transactions, raising over $15 billion in aggregate. Ms. Schulz also has significant experience with the U.S. Securities and Exchange Commission (SEC) and International Financial Reporting Standards (IFRS). As one of the founding members and senior partners in EY’s Life Sciences Practice, Ms. Schulz directly contributed to the growth of EY into a $45B firm recognized on the Fortune 100 Best Companies to Work For® list 22 years in a row. She is also qualified to serve as a financial expert under SEC, NYSE and NASDAQ rules.

M. Levine was appointed as a member of the Board of Directors in January 2025. Mr. Levine is a strategic business leader with decades of diverse global board and executive management experience within the medical technology industry. He possesses a deep expertise in portfolio transformation, strategic business development and driving shareholder value. From 2012 to 2022, Mr. Levine served as President, Chief Executive Officer, and Director of Accuray Incorporated, where he led a transformative turnaround that involved all strategic, operational, and financial activities that restored the business to consistent top line growth, positive operating profit, free cash flow (EBITDA), and expanded the company’s global footprint. Before joining Accuray, Mr. Levine served as President, Chief Executive Officer, and Board Member of Immucor, Inc. (Nasdaq: BLUD), where he led the transition from the company being publicly traded up until its acquisition as a private entity by TPG Capital in August 2011 for approximately $2 billion. From 2004 to 2010, Mr. Levine served as President, Chief Executive Officer and Board Member of Mentor Corporation (NYSE: MNT), where he played an instrumental role in repositioning the company by executing a strategic transformation focused on higher growth markets, ultimately leading to the company’s acquisition by Johnson & Johnson (J&J) in June 2008 for $1.2 billion.